Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001–2006)

Daw, Jamie R.; Mintzes, Barbara; Law, Michael R.; Hanley, Gillian E.; Morgan, Steven G.

doi:10.1016/j.clinthera.2011.11.025

Cited by 90 publications

(108 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to one study when non steroidal antiinflammatory drugs are administered in the second and third trimester of pregnancy they are significantly associated with low birth weight, asthma of 18 month old children and maternal vaginal bleeding (17). This finding have shown lower prescription of harmful drugs from category D (8.8%) and category X (0.4%) than the study done in Ethiopia where 16.8% were Category D and 7.1% Category X 13 , but higher than the study done in United States (4.8%) 18 and Canada (5.5%) 19 of prescribing harmful drugs from category D, but a bit lower pattern of prescription from category X (0.4%) than in United states (4.6%) 18 and Canada (2.5%) 19 . These variations might be due to lack of knowledge, training and experience of prescribers or variation in sample size of this study than the studies in United States and Canada for prescribing category D drugs and viceversa for category X prescription.…”

Section: Discussionmentioning

confidence: 71%

Assessment of Drug Use and Effect in Pregnant Women Attending Antenatal Care in Hospitals of Mekelle, Tigray, Ethiopia

Gebremichael

2014

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 71%

Assessment of Drug Use and Effect in Pregnant Women Attending Antenatal Care in Hospitals of Mekelle, Tigray, Ethiopia

Gebremichael

2014

J. Drug Delivery Ther.

View full text Add to dashboard Cite

“…76 Similarly, paroxetine has a very low milk/plasma ratio; preliminary data also suggest that escitalopram has a low relative infant dose and is largely undetectable in the infant after feeding. 77 Overall, treatment of perinatal GAD with SSRI/SNRIs should be determined on a case-by-case basis. Patients with prior history of SSRI/SNRI intake should continue on the drug they have been taking in order to reduce the probability of relapse, with the exception perhaps of paroxetine, due to the potential cardiac risks to the fetus.…”

Section: Antidepressantsmentioning

confidence: 99%

“…77 They appear effective at rapidly treating short-term anxiety, particularly its somatic symptoms. 78 Because antidepressants require several weeks before the onset of their action, benzodiazepines can be used for brief, pro re nata treatment in order to produce an immediate anxiolytic response.…”

Section: Benzodiazepinesmentioning

confidence: 99%

Perinatal Generalized Anxiety Disorder: Assessment and Treatment

Misri

Abizadeh

Sanders

et al. 2015

Journal of Women's Health

View full text Add to dashboard Cite

Perinatal generalized anxiety disorder (GAD) has a high prevalence of 8.5%-10.5% during pregnancy and 4.4%-10.8% postpartum. Despite its attendant dysfunction in the patient, this potentially debilitating mental health condition is often underdiagnosed. This overview will provide guidance for clinicians in making timely diagnosis and managing symptoms appropriately. A significant barrier to the diagnosis of GAD in the perinatal population is difficulty in distinguishing normal versus pathological worry. Because a perinatal-specific screening tool for GAD is nonexistent, early identification, diagnosis and treatment is often compromised. The resultant maternal dysfunction can potentially impact mother-infant bonding and influence neurodevelopmental outcomes in the children. Comorbid occurrence of GAD and major depressive disorder changes the illness course and its treatment outcome. Psychoeducation is a key component in overcoming denial/stigma and facilitating successful intervention. Treatment strategies are contingent upon illness severity. Cognitive behavior therapy (CBT), relaxation, and mindfulness therapy are indicated for mild GAD. Moderate/severe illness requires pharmacotherapy and CBT, individually or in combination. No psychotropic medications are approved by the FDA or Health Canada in pregnancy or the postpartum; off-label pharmacological treatment is instituted only if the benefit of therapy outweighs its risk. SSRIs/SNRIs are the first-line treatment for anxiety disorders due to data supporting their efficacy and overall favorable side effect profile. Benzodiazepines are an option for short-term treatment. While research on atypical antipsychotics is evolving, some can be considered for severe manifestations where the response to antidepressants or benzodiazepines has been insufficient. A case example will illustrate the onset, clinical course, and treatment strategies of GAD through pregnancy and the postpartum.

show abstract

“…Up to 20% of mothers experience antenatal depression and anxiety disorders and 5-8% of infants are born with in utero exposure to SRIs (3).…”

mentioning

confidence: 99%

Prenatal exposure to serotonin reuptake inhibitor antidepressants and childhood behavior

2015

Self Cite

View full text Add to dashboard Cite

Background: Animal research has suggested that prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure causes increased anxiety-like behaviors in adulthood. We examined whether in utero SRI exposure influenced externalizing and internalizing behaviors in children at 3 y and again at 6 y of age. Methods: We recruited women in their second trimester of pregnancy from primary maternity care providers in Vancouver British Columbia, Canada. We compared the internalizing, externalizing, and the anxious and attention subscales of the internalizing behaviors scores of children exposed to SRIs and children not exposed to SRIs at age 3 and age 6. results: We included 110 mother-child pairs (44 exposed to SRI and 66 not exposed). Higher levels of internalizing and anxious behaviors were reported in SRI exposed children at both 3 and 6 y of age compared with children who were not exposed (F = 7.52, P = 0.0072 and F = 7.91, P = 0.0058, respectively). The fully adjusted hierarchical regression models indicated a positive and significant relationship between SRI exposure and increased internalizing and anxious behaviors even when controlling for maternal mood during pregnancy, postpartum and childhood. conclusion: SRI exposure was associated with sustained higher levels of internalizing behaviors in early childhood even when controlling for maternal depression.

show abstract

Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001–2006)

Cited by 90 publications

References 25 publications

Assessment of Drug Use and Effect in Pregnant Women Attending Antenatal Care in Hospitals of Mekelle, Tigray, Ethiopia

Assessment of Drug Use and Effect in Pregnant Women Attending Antenatal Care in Hospitals of Mekelle, Tigray, Ethiopia

Perinatal Generalized Anxiety Disorder: Assessment and Treatment

Prenatal exposure to serotonin reuptake inhibitor antidepressants and childhood behavior

Contact Info

Product

Resources

About